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Background/Aims. At present, there is no simple test for predicting severity in acute pancreatitis. We investigated the use of an
assay of soluble E-cadherin (sE-cadherin). Methods. Concentrations of sE-cadherin, from 19 patients with mild acute pancreatitis,
7 patients with severe acute pancreatitis, 11 patients with other acute gastrointestinal pathologies, and 12 healthy subjects were
measured using a commercially available sandwich ELISA kit based on two monoclonal antibodies speciﬁc to the extracellular
fragment of human E-cadherin. Measurements were made at 12 hours or less from onset of pain and also at 24 and 48 hours
after onset of pain. Results. Mean (standard deviation) concentration of sE-cadherin in patients with severe acute pancreatitis at
<12 hours was 17780ng/mL (7853), signiﬁcantly higher than that of healthy volunteers 5180ng/mL (1350), P = .0039, patients
with other gastrointestinal pathologies 7358ng/mL (6655), P = .0073, and also signiﬁcantly higher than that of patients with mild
pancreatitis, 7332ng/mL (2843), P = .0019. Discussion. Serum sE-cadherin could be an early (within 12 hours) objective marker
of severity in acute pancreatitis. This molecule warrants further investigation in the form of a large multicentre trial.
Copyright © 2009 A. Sewpaul et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
More than a century after its comprehensive description
by Fitz [1], acute pancreatitis remains a common disorder
withpotentiallydevastatingconsequences.Theincidencehas
been reported to be as high as 38 per 100000 population per
year [2] with around 25% of patients developing severe or
life-threatening complications that require high-dependency
nursing or intensive care support. Even though the overall
mortality over the past 30 years has fallen from 25%–30% to
6%–10%, it has remained at that level for a decade or more
[3]. If complications develop, however, mortality increases
to 35% or higher [4], with 50% of deaths occurring within
one week of the attack, mostly from multiorgan dysfunction
syndrome (MODS) [5].
It is generally accepted that all patients with signs of
moderate-to-severe acute pancreatitis should be admitted
to an intensive care unit and referred to specialised centres
for maximum supportive care [6–8]. As complications may
develop at any time, frequent reassessment and continuous
monitoring are necessary. The most important supportive
therapy is adequate and prompt ﬂuid resuscitation with
intravenous ﬂuids and supplemental oxygen, with a liberal
indication for assisted or controlled ventilation to guarantee
optimal oxygen transport [7–9].
To date, inhibition of any known pathogenic step (by,
e.g., octreotide, gabexate mesilate, and lexipafant) has not
eﬀectively reduced mortality or increased long-term survival
insevereacutepancreatitis[10–12].Thus,treatmentofacute
pancreatitis in the early stages is still symptomatic, with no
speciﬁc medication being currently available.
UK guidelines [8] recommend that severity stratiﬁcation
is attempted but presently there is no tool that can predict,
with a high degree of accuracy, within 48 hours from the
onset of pain, which patients will develop severe disease.
Initial clinical assessment alone identiﬁes fewer than half the
patients with severe acute pancreatitis [13]. Scoring systems
incorporating clinical, biochemical, or radiological criteria
for severity assessment have been in use for some decades.
These include the 11 criteria described by Ranson in 1970
[14], the Glasgow score (eight criteria) [15], and the acute
physiology and chronic health evaluation (APACHE II) score
(14 criteria) [16]. The sensitivity and speciﬁcity of these
scoring systems for predicting severe acute pancreatitis range2 HPB Surgery
between 55% and 90%, depending on the cutoﬀ number
andthetimingofscoringusuallyreachingoptimalsensitivity
and speciﬁcity at 48 hours [17, 18]. The ideal severity
stratiﬁcationsystemwouldbebasedonasimple-to-perform,
aﬀordable, single, and quick test that is widely available
and has a high sensitivity and speciﬁcity very early in the
diseaseprocess.Theuseofsinglepredictivemarkershasbeen
investigated in the past.
Serum amylase and lipase, the standard tests for acute
pancreatitis diagnosis, are poor predictors of severity [19].
Novel markers for the early prediction of acute pancreatitis
severity include the pancreatic proenzyme trypsinogen-2
and its subunit TAP [20, 21], as well as early inﬂam-
matory response markers such as serum IL-6 [22, 23],
procalcitonin[24,25],polymorphonuclearelastase[26],and
serum amyloid A [27]. The more established marker C-
reactive protein has been shown to be an accurate severity
predictor (sensitivity and speciﬁcity above 80%) at 48 hours
postsymptom onset if a cutoﬀ level of 150 mg/L is used [6].
Unfortunately, for a variety of reasons (poor predictive value
before 48 hours, conﬂicting reports, and diﬃcult laboratory
measurement), none of these single tests have made the tran-
sition from the research setting into widespread clinical use.
1.1. E-Cadherin. E-cadherin is a 120-kDa transmembrane
glycoprotein involved in the calcium dependent adhesion
of all epithelial cells. Soluble E-cadherin is an 80-kDa
peptide degradation product of the 120-kDa E-cadherin
molecule which is generated by a calcium ion dependent
proteolytic process [28, 29]. Matrix metalloproteinases,
trypsin, kallikrein 7, and plasmin are examples of molecules
that are capable of performing this proteolytic process [28–
37] (see Figure 1). The maintenance of epithelial membranes
in healthy individuals involves a continuous turnover of E-
cadherin, and independent of age and sex, low levels of sE-
cadherin are found in the serum [38].
Elevated serum levels of sE-cadherin are found in
patients with certain malignancies, including pancreatic [30,
36, 38–45]. It has been suggested that these increased levels
are due to the cleavage of membrane-bound E-cadherin by
tumour-derived proteases.
In a previous study by Pittard et al., signiﬁcantly elevated
levels of sE-cadherin were found in patients exhibiting a
systemic inﬂammatory response. Importantly, these elevated
sE-cadherin levels were found within an early time frame
of the disease process and correlated to the severity of the
developed inﬂammatory response [46].
A systemic inﬂammatory response is seen in acute
pancreatitis. Therefore, it is probable that sE-cadherin is
cleavedfrommembrane-boundE-cadherinbyinﬂammatory
proteases. If this also occurs early in the inﬂammatory
response in acute pancreatitis, and measurable serum levels
ofsE-cadherinrelatetotheseverityofthedevelopingdisease,
then this molecule could be used to predict disease severity.
To test this hypothesis, we investigated, using a prospective
pilot study, whether serum levels of sE-cadherin measured at
an early time point following the onset of symptoms (within
12, 24, and 48 hours) in patients with acute pancreatitis
were signiﬁcantly diﬀerent in patients who went on to
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Figure 1: (a) The zipper model for cadherin interaction showing
homophilic interactions between E-cadherin molecules expressed
on the cell membranes; (b) proteolytic cleavage of the extracellular
portion of the E-cadherin fragment generating soluble E-cadherin.
develop mild, compared to severe disease. As serum levels
of sE-cadherin are elevated in many diﬀerent inﬂammatory
processes, its use in the diagnosis of acute pancreatitis was
not investigated as it is likely to be of limited value.
2. Patients andMethods
2.1. Study Population. Patients admitted to the Newcastle
NHS hospitals with acute pancreatitis were assessed for
inclusion in the study. Acute pancreatitis was deﬁned as
acute abdominal pain with a typical clinical picture and a
serum amylase level at least three times the upper limit of
normal and/or typical ﬁndings on computed tomography.
We excluded patients who had chronic pancreatitis, known
malignancies, or were under 18 years. Clinical, pathological,
and radiological patient data was collected prospectively on
a database.
We enrolled by parallel recruitment a number of patients
admitted with other abdominal inﬂammatory pathologies
such as acute diverticulitis, perforated duodenal ulcer,
cholangitis, acute appendicitis, and acute cholecystitis. A
third group of healthy volunteers was also recruited. The
same exclusion criteria applied to the patients with acute
pancreatitis.
2.2. Study Design. Ethical approval was obtained from the
Newcastle and North Tyneside Health Authority, UniversityHPB Surgery 3
of Newcastle upon Tyne and University of Northumbria at
Newcastle, and Joint Ethics Committee.
Following informed consent, three blood samples, for
sE-cadherin measurement, were taken from each individual.
The ﬁrst measurement was taken from the admission blood
sample. The subsequent three samples were taken at 12, 24,
and 48 hours after the onset of pain. Samples were subjected
to centrifugationwithin 60 minutes and stored at −20◦C.sE-
cadherinlevelsweremeasuredusingacommerciallyavailable
sandwich ELISA kit from Takara Shuzo, Japan. In brief, the
capturemonoclonal antibody iscoatedontomicrotitreplate.
Following blocking of nonspeciﬁc binding, patient samples,
or standard solutions is incubated in the wells at 37◦Cf o r2
hours. The detection monoclonal antibody (conjugated with
peroxidase) is then incubated in the above wells at 37◦C
for 1 hour. The addition of peroxidase substrate solution
(H2O2 and tetramethylbenzibine) results in a colour change.
The reaction was terminated by the addition of 1M H2SO4.
Absorbance was measured with the microtitre plate reader at
450nm. Each sample was measured three times and a mean
value derived. Sample concentrations were determined from
standard curves obtained from standard solutions.
Patients with local and/or organ failure were deﬁned
as having severe acute pancreatitis according to the Atlanta
classiﬁcation [47].
Data was analysed using GraphPad PRISM (version
3.0). The data for sE-cadherin levels were compared using
the Mann-Whitney U-test. Diﬀerences were considered as
signiﬁcant when P<. 05.
3. Results
3.1. Patients. A total of 49 patients were recruited into the
study; all met the eligibility criteria. 26 patients had acute
pancreatitis, 12 had other acute abdominal pathologies, and
11 were healthy controls.
Theoverallmedianageofpatientswithacutepancreatitis
was 56 (range 24–87); 12 were men. 19 patients had mild
disease,andtheremaining7hadseveredisease.Theaetiology
was gallstones in 13 patients (9 mild and 4 severe). Alcohol
was the cause in 4 (3 mild and 1 severe). ERCP was the cause
in 3 patients (2 mild and 1 severe). No obvious cause was
found in 6 patients (5 mild and 1 severe). None of the mild
cases and 1 of the severe cases died.
The median age of the 12 healthy controls (4 male) was
29 (range 21–54).
The median age of the 11 patients with other acute
abdominal pathologies (5 male) was 59 (range 29–72). The
ﬁnal diagnoses for these patients were as follows: gastroen-
teritis 1; gastritis 1; acute cholecystitis 2; acute appendicitis 2;
diverticulitis 1; cholangitis 1; perforated peptic ulcer 3.
3.2. Serum sE-Cadherin Levels. At less than 12 hours from
onset of pain, the mean (standard deviation) concentration
of sE-cadherin in patients with severe acute pancreatitis was
17780ng/mL (7853), signiﬁcantly higher than that of healthy
volunteers 5180ng/mL (1350), P = .0039 (see Figure 2).
In contrast, the mean (SD) concentration of sE-cadherin in
patientswithmildacutepancreatitiswas7332ng/mL(2843),
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Figure 2: sE-cadherin concentration in patients at 12 hours or less
after onset of pain. Data are shown as a scatter plot with the mean
represented by a solid line.
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Figure 3: sE-cadherin concentration in patients at 24 hours after
onset of pain. Data are shown as a scatter plot with the mean
represented by a solid line.
and the mean concentration of sE-cadherin in patients with
other pathologies was 7358ng/mL (6655). The mean level in
mild acute pancreatitis patients was also signiﬁcantly higher
than that of healthy volunteers (P = .0166), but not in
those with other pathologies (P = .3909). Importantly,
signiﬁcantly higher levels of sE-cadherin were detected in
patients with severe acute pancreatitis within 12 hours
following onset of pain (mean 17780ng/mL) compared to
mild pancreatitis (mean 7332ng/mL), P = .0019 and those
with other gastrointestinal pathologies (mean 7358ng/mL),
P = .0073.
At 24 hours after the onset of pain, the mean (SD) sE-
cadherin concentration was 14320ng/mL (7532) in patients
with severe acute pancreatitis, still signiﬁcantly higher than
that of healthy volunteers 5518ng/mL (1518), P = .0030 and
also compared to those with mild pancreatitis 6474ng/mL
(2823) P = .0065 (see Figure 3).
At 48 hours the mean (SD) sE-cadherin concentration
was 13360ng/mL (6440) in patients with severe acute
pancreatitis, still signiﬁcantly higher than that of healthy
volunteers 4928ng/mL (1314) P = .0080, and also compared
to those with mild pancreatitis 5818ng/mL (1899) P = .0076
(see Figure 4).4 HPB Surgery
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Figure 4: sE-cadherin concentration in patients at 48 hours after
onset of pain. Data are shown as a scatter plot with the mean
represented by a solid line.
4. Discussion
In the clinical setting of a patient with acute pancreati-
tis, initial therapy, accurate severity stratiﬁcation, and an
appropriate facility for patient management are of major
interest for the admitting clinician. At present, there is no
methodbywhichtoaccuratelypredictseverity.Manyscoring
systems have been proposed but all have their drawbacks.
The possibility that an aﬀordable, quick, single, and accurate
test may exist has led clinicians to investigate numerous
(mainly inﬂammatory mediators) biochemical molecules.
Many have been assessed and detected either in serum or
urine but for a number of reasons have failed to reach the
clinical setting.
This study has shown that serum levels of sE-cadherin
can be used to predict severity of acute pancreatitis at an
early time point, with the mean diﬀerences in sE-cadherin
concentration being statistically diﬀerent within 12 hours
or less or at 24 hours after the onset of pain. Further-
more, although not presently widely available, this test is
quick, aﬀordable (comparable to CRP), and could easily be
incorporated into hospital practice. It is thought that sE-
cadherin, elevated levels of which are found in inﬂammatory
conditions, originates via cleavage from membrane-bound
E-cadherin. The mechanism by which and at exactly which
point during an inﬂammatory process this occurs is not
presently fully understood. Experimentally, molecules such
as metalloproteinases, kallikrein 7, plasmin, and trypsin have
allbeenshowntobecapableofperformingthiscleavagepro-
cess [28–37]. With regard to metalloproteinases, it is known
that they can cause organ damage [48] and have a tissue
remodelling role in the regeneration following an attack
of pancreatitis, but recently evidence is emerging that they
could be important in early inﬂammatory events. Not only
have elevated levels of MMP-2 and MMP-9 been reported in
the peritoneal ﬂuid of rats following sodium taurocholate-
induced pancreatitis [48], but also MMP-3 and MMP-9
enzyme activity has been shown to be elevated 12 hours
after cerulein-induced pancreatitis [49]. Therefore, trypsin
and/or MMP activation very early in the pathogenesis of
acute pancreatitis could be one mechanism by which the
elevated levels of sE-cadherin are achieved.
In a recent study, Steinhusen et al. [35] reported that
during apoptosis, fragments of E-cadherin with apparent
molecular masses of 24, 29, and 84kDa were generated by
two distinct proteolytic activities. In addition to a caspase-
3-mediated cleavage releasing the cytoplasmic domain of E-
cadherin, a metalloproteinase sheds the extracellular domain
from the cell surface during apoptosis. In experimental
pancreatitis, it has been found that acute pancreatitis is
associated with the induction of acinar cell apoptosis, the
degree of which mimics the severity of pancreatitis [50].
ThemeansE-cadherinconcentrationswerehigherinour
healthy controls compared with those reported in one study
(5180ng/mL versus 2515ng/mL, resp.) [40], but similar to
levelsfoundinamorerecentstudy(5616ng/mL)[42].Racial
diﬀerences between groups have been suggested as an expla-
nation, but we suspect that the ELISA substrate used is the
reason. The substrate used was o-Phenylenediamine (OPD)
in the former study [40]a n d3 , 3  ,5,5 -Tetramethylbenzidine
(TMB) in our own and the latter study [42] where compara-
ble sE-cadherin levels were found.
Prior to our study, we suspected that raised sE-cadherin
levels would be found in all patients experiencing an
inﬂammatory event. From our results, it appeared that this
was not the case, and that raised sE-cadherin levels were
only found in patients with an inﬂammatory insult that
resulted in signiﬁcant multiorgan failure. The solitary high
sE-cadherin level measured in the group of patients with
other pathologies was from a patient with cholangitis who
did go on to develop multiorgan failure.
Of the seven patients who had the severe form of acute
pancreatitis,6hadsigniﬁcantlyelevatedlevelsofsE-cadherin
within 12 hours from the onset of pain. These patients
required admission to critical care for organ support within
24 hours of their presentation to hospital and went on to
develop MOF. The remaining patient, whose sE-cadherin
level was not signiﬁcantly raised within 12 hours after the
onset of pain, is worthy of further discussion. This female
patient presented with gallstone pancreatitis was managed
initially on the general ward. A further bout of pain,
however, developed on day 4 following admission for which
she needed HDU care on day 5. She went on to develop
multiorgan failure and pancreatic necrosis. It is possible
that there may have been a second attack of pancreatitis
induced on day 4 in an inpatient and that she subsequently
developed severe acute pancreatitis and necrosis from this
second attack. Unfortunately, we do not have serum sE-
cadherin levels relating to this second bout of pain.
Despite the small sample size in this study, sE-cadherin
seemstobeanexcitingpotentialveryearlymarker(within12
hours of onset of symptoms) of severity in acute pancreatitis.
It is noted however that this is a small pilot study and that
ﬁrm conclusions cannot be drawn until the hypothesis has
been tested on a larger population. A larger sample size
would permit more sophisticated statistical analysis. The
predictive value of sE-cadherin could then be evaluated by
receiver-operating characteristic (ROC) curves to determine
the optimal cutoﬀ value to predict severe AP. Sensitivity
and speciﬁcity, as well as positive and negative predictive
values, could then be calculated. This would also allow for aHPB Surgery 5
usefulcomparisonoftheprognosticvalueofE-cadherinwith
other predictive scores. We therefore feel that this molecule
warrants further study in the form of a multicentre trial.
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